nortriptyline has been researched along with Degenerative Diseases, Central Nervous System in 2 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to characterize the neuroprotective effects of nortriptyline, a tricyclic antidepressant, in mouse models of chronic neurodegeneration [amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD)]." | 3.74 | Nortriptyline delays disease onset in models of chronic neurodegeneration. ( Cormier, K; Ferrante, RJ; Friedlander, RM; Guan, Y; Huo, C; Kristal, BS; Smith, K; Stavrovskaya, IG; Wang, H; Wang, X; Zhu, S, 2007) |
| " Findings from in vitro aggregation and kinetics assays support the view that NOR inhibits aggregation of α-syn by directly binding to the soluble, monomeric form, and by enhancing reconfiguration of the monomer, inhibits formation of toxic conformations of the protein." | 1.46 | Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. ( Collier, TJ; de Oliveira, P; Dettmer, U; Feany, MB; Grammatopoulous, T; Havas, D; Hutter-Paier, B; Jock, K; Justman, C; Lansbury, P; Lapidus, L; Liu, F; Paumier, KL; Prokesch, M; Rochet, JC; Sortwell, CE; Srivastava, KR; Stirtz, GL, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collier, TJ | 1 |
| Srivastava, KR | 1 |
| Justman, C | 1 |
| Grammatopoulous, T | 1 |
| Hutter-Paier, B | 1 |
| Prokesch, M | 1 |
| Havas, D | 1 |
| Rochet, JC | 1 |
| Liu, F | 1 |
| Jock, K | 1 |
| de Oliveira, P | 1 |
| Stirtz, GL | 1 |
| Dettmer, U | 1 |
| Sortwell, CE | 1 |
| Feany, MB | 1 |
| Lansbury, P | 1 |
| Lapidus, L | 1 |
| Paumier, KL | 1 |
| Wang, H | 1 |
| Guan, Y | 1 |
| Wang, X | 1 |
| Smith, K | 1 |
| Cormier, K | 1 |
| Zhu, S | 1 |
| Stavrovskaya, IG | 1 |
| Huo, C | 1 |
| Ferrante, RJ | 1 |
| Kristal, BS | 1 |
| Friedlander, RM | 1 |
2 other studies available for nortriptyline and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antidepressive Agents, Tricyclic; Brain; Ce | 2017 |
Nortriptyline delays disease onset in models of chronic neurodegeneration.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antidepressive Agents, Tricyclic; Apoptosis; Brain; Chronic | 2007 |